Oncozenge AB (ONCOZ) - Net Assets
Based on the latest financial reports, Oncozenge AB (ONCOZ) has net assets worth Skr9.30 Million SEK (≈ $1.00 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr19.84 Million ≈ $2.13 Million USD) and total liabilities (Skr10.53 Million ≈ $1.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of Oncozenge AB for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr9.30 Million |
| % of Total Assets | 46.9% |
| Annual Growth Rate | -23.65% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 97.18 |
Oncozenge AB - Net Assets Trend (2020–2024)
This chart illustrates how Oncozenge AB's net assets have evolved over time, based on quarterly financial data. Also explore ONCOZ total assets for the complete picture of this company's asset base.
Annual Net Assets for Oncozenge AB (2020–2024)
The table below shows the annual net assets of Oncozenge AB from 2020 to 2024. For live valuation and market cap data, see how much is Oncozenge AB worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr9.95 Million ≈ $1.07 Million |
-46.62% |
| 2023-12-31 | Skr18.64 Million ≈ $2.01 Million |
-45.13% |
| 2022-12-31 | Skr33.97 Million ≈ $3.66 Million |
-57.70% |
| 2021-12-31 | Skr80.32 Million ≈ $8.64 Million |
+174.32% |
| 2020-12-31 | Skr29.28 Million ≈ $3.15 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oncozenge AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5992400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.30 Million | 13.08% |
| Other Components | Skr84.41 Million | 848.34% |
| Total Equity | Skr9.95 Million | 100.00% |
Oncozenge AB Competitors by Market Cap
The table below lists competitors of Oncozenge AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dovre Group Plc
HE:DOV1V
|
$9.07 Million |
|
Newcity (Bangkok) Public Company Limited
BK:NC
|
$9.08 Million |
|
Fountain
BR:FOU
|
$9.09 Million |
|
Patkol Public Company Limited
BK:PK
|
$9.09 Million |
|
Resources & Energy Group Ltd
AU:REZ
|
$9.07 Million |
|
Kwang Hee Self-Administered Real Estate
KO:140910
|
$9.07 Million |
|
Pacific Ridge Exploration Ltd
V:PEX
|
$9.06 Million |
|
MESB Bhd
KLSE:7234
|
$9.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncozenge AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,641,000 to 9,950,000, a change of -8,691,000 (-46.6%).
- Net loss of 8,688,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-8.69 Million | -87.32% |
| Other Changes | Skr-3.00K | -0.03% |
| Total Change | Skr- | -46.62% |
Book Value vs Market Value Analysis
This analysis compares Oncozenge AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.98x to 7.06x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Skr2.01 | Skr6.00 | x |
| 2021-12-31 | Skr6.86 | Skr6.00 | x |
| 2022-12-31 | Skr2.90 | Skr6.00 | x |
| 2023-12-31 | Skr1.59 | Skr6.00 | x |
| 2024-12-31 | Skr0.85 | Skr6.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncozenge AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -87.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -868800.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.15x
- Recent ROE (-87.32%) is below the historical average (-63.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -2.17% | 0.00% | 0.00x | 1.31x | Skr-3.56 Million |
| 2021 | -4.84% | 0.00% | 0.00x | 1.06x | Skr-11.92 Million |
| 2022 | -137.30% | 0.00% | 0.00x | 1.09x | Skr-50.04 Million |
| 2023 | -85.31% | -530066.67% | 0.00x | 1.09x | Skr-17.77 Million |
| 2024 | -87.32% | -868800.00% | 0.00x | 1.15x | Skr-9.68 Million |
Industry Comparison
This section compares Oncozenge AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncozenge AB (ONCOZ) | Skr9.30 Million | -2.17% | 1.13x | $9.07 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.